Skip to content

Savara SVRA Price / book

Price / book at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
76.9×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
2.7×-7.2×
Innoviva, Inc. logo
Innoviva, Inc.INVA
1.3×
Theravance Biopharma logo
Theravance BiopharmaTBPH
2.9×+0.2×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
3.1×-0.4×
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
22×+7.8×

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+236%
Enterprise value$1.19B+224%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Calculated from Savara’s reported figures.

Based on the most recent quarter.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's price / book?
Savara (SVRA) reported price / book of 6.3× in Q1 2026.
How has Savara's price / book changed year-over-year?
Savara's price / book increased by 96.3% year-over-year, from 3.2× to 6.3×.
What is the long-term trend for Savara's price / book?
Over 5 years (2020 to 2025), Savara's price / book has grown at a 34.4% compound annual growth rate (CAGR), from 1.4× to 6×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.